Glenmark receives ANDA approval for Clobetasol Propionate Foam, 0.05%
10 September 2019 | News
It is a generic version of Olux®-E Foam, 0.05%, of Mylan Pharmaceuticals Inc.
Glenmark Pharmaceuticals has been granted final approval by the United States Food & Drug Administration for Clobetasol Propionate Foam, 0.05% (Emulsion Formulation), a generic version of Olux®-E Foam, 0.05%, of Mylan Pharmaceuticals Inc
According to IQVIATM sales data for the 12 month period ending July 2019, the Olux®-E Foam, 0.05% market2 achieved annual sales of approximately $11.1 million.
Glenmark’s current portfolio consists of 161 products authorized for distribution in the U.S. marketplace and 54 ANDA’s pending approval with the USFDA.
